Verve Ventures’ Post

As 2023 is coming to an end, we at Secarna Pharmaceuticals would like to thank our exceptional team, partners and stakeholders for their dedication and hard work they invest to jointly reach our goals in the dynamic field of antisense therapeutics. During this successful year, we initiated new research projects, developed novel antisense oligonucleotides (#ASOs) with best-in-class potential in multiple indications, and had the opportunity to share our achievements with the community through various scientific publications and conferences. We expanded our collaboration network and have continued to enhance our expertise in identifying diseases, targets and tissues most fitting to our platform technology. Our most advanced proprietary immune-oncology program SECN-15 targeting NRP1 has further progressed, and IND-enabling steps have been initiated. In addition, out of our partnered pipeline, Lipigon’s lead compound, Lipisense®, successfully went through clinical phase 1 with exciting data and the start of phase 2 is expected soon. In 2024, we will continue to innovate our technology platform towards organ and cell-specific antisense therapeutics to further solidify our position in the field, and to offer transformative solutions in healthcare to our biotech and pharma partners, pushing the boundaries of current treatment possibilities. We are excited to find what 2024 holds for us. See you next in San Francisco during J.P. Morgan Week! #Innovation #YearInReview #antisensetherapeutics #JPMorgan2024

🔍 Q2's Biotech arena: A trend towards sharp, strategic deals after Q1. Novartis' $1B dive into Mariana Oncology highlights targeted oncology investments. 💡 Biogen's $1.15B HI-Bio acquisition showcases a bet on novel immune therapies, while Merck's major $3B Eyebiotech deal underscores a focus on eye health. 🎯 IPOs saw a cautious quartet, with Actuate and Rapport out front, indicating a selective approach in a fluctuating market. In short, Q2 prioritized strategic over sheer volume in Biotech M&A and IPOs. 🧬💼 #Biotech #Investment #MnA #Quality

Wondering which companies bagged the biggest private biotech investments in May 2024? 💰🔬 Well, Uniquity Bio came out on top after raising $300 million in a private equity round. 🥇 Meanwhile, AltruBio Inc. came second, having raised $225 million in a series B round, and BridgeBio Oncology Therapeutics came third with a $200 million private equity financing. 🥈🥉 Around the world, oncology and immunology players attracted the biggest funding rounds overall. 🌍💉 To find out more, check out our latest article! 👇 https://lnkd.in/dSbyrP-K #biotechinvestments #venturecapital #oncology #immunology #biotechfunding #privateequity #biotechnews #healthcareinnovation #medicalresearch Zenas BioPharma | Bluejay Therapeutics | Pheon Therapeutics | Lycia Therapeutics | Attovia Therapeutics | Reunion Neuroscience | Ajax Therapeutics | Aardvark Therapeutics | CinRx Pharma | Delphia Therapeutics | Latus Bio | Grey Wolf Therapeutics | Prologue Medicines | LabGenius | Imvax, Inc. | Gameto

Lantheus Holdings (LNTH) Stock Surge 🚀 Lantheus Holdings (NASDAQ: LNTH) has recently experienced a significant surge in its stock price, with an approximately 59.74% increase in the past week. Here’s why: 1. CMS Proposed Rule: On July 10, Lantheus welcomed a CMS proposed rule to improve payment for specialized diagnostic radiopharmaceuticals, enhancing patient access and boosting market confidence. 2. Strategic Acquisitions: Acquired global rights to innovative cancer diagnostics and therapeutics, expanding their market presence. 3. Technological Innovations: Launched AI-enabled solutions like aPROMISE on Siemens Healthineers' platform, showcasing their cutting-edge capabilities. 4. Positive Analyst Ratings: Truist Securities raised its price target from $96 to $141, maintaining a "Buy" rating. The higher target is based on increased valuation for Lantheus' Pylarify, a diagnostic agent for prostate cancer, driven by less pricing pressure and reduced long-term share loss. ✅ LNTH ranked 7th in our May quantitative report and has surpassed the target price level, achieving a remarkable near 100% increase since the launch of the report. ✅ #LantheusHoldings #StockRally #HealthcareInnovation #StrategicGrowth #Investing

Discover how Bluejay Therapeutics

💡𝗖𝗼𝗺𝗽𝗮𝗻𝘆 𝗦𝗽𝗼𝘁𝗹𝗶𝗴𝗵𝘁 💡Pheon Therapeutics! 🧑💼𝗙𝗼𝘂𝗻𝗱𝗲𝗱: Pheon Therapeutics was founded on September 28, 2022 by Bertrand Damour. A seasoned biotech entrepreneur with over 20 years of experience in the industry, he has led several successful biotech companies in both Europe and the US. 🔬𝗦𝗽𝗲𝗰𝗶𝗮𝗹𝗶𝘇𝗲𝗱 𝗜𝗻: Pheon Therapeutics is a leading Antibody-Drug Conjugate (ADC) specialist, developing next-generation ADCs to treat a wide range of hard-to-treat cancers. Their approach leverages a proprietary payload platform to create highly effective and safe ADCs, offering new hope for patients with solid tumors and liquid cancers that do not respond to other treatments. 💰𝗙𝘂𝗻𝗱𝗶𝗻𝗴: We are thrilled to announce that Pheon Therapeutics launched on September 28, 2022, with an impressive $68 million in Series A funding. Additionally, on May 21, 2024, we successfully completed a $120 million Series B financing to further develop our pipeline of differentiated ADCs. 🤝𝗜𝗻𝘃𝗲𝘀𝘁𝗼𝗿𝘀: The Series A funding was led by Brandon Capital, Forbion, and Atlas Venture. Their recent Series B financing was led by TCGX with participation from new investors BVF PARTNERS, L.P, Lightspeed, and Perceptive Advisors, alongside existing investors Atlas Venture, Brandon Capital, Forbion, and Research Corporation Technologies. #biotech #innovation #cancerresearch #adcs #fundingnews #buyingsimplified

Our portfolio company HAYA Therapeutics has been recognized by Labiotech.eu as one of the top 18 biotech startups in Switzerland, spotlighting its innovative approach to targeting non-coding RNAs to combat fibrotic diseases and age-related conditions: https://lnkd.in/gnPbAhQ As reported by The Financial Times, a groundbreaking anti-aging therapy that mimics regenerative processes seen in axolotl salamanders has shown promise in extending the lifespan of mice by 25%. Read more about the treatment that targets the pro-inflammatory protein IL-11: https://lnkd.in/guvdqyFH New hires at our portfolio companies: HAYA Therapeutics welcomes Eric Adam as their new COO, bringing his extensive experience from the pharmaceutical and diagnostics industries to support their growth and scientific exploration. Meanwhile, Auron Therapeutics, Inc. introduces Serge Messerlian to their board, enhancing their leadership as they advance their innovative cancer therapeutics platform. #ICYDK #ApolloVC #Lifespan #Healthspan #Longevity #VentureCapital

Initial Biotech IPO's are off to a great start in 2024! ...ArriVent Biopharma will join the Nasdaq on Friday morning in a strong start to biotech’s first batch of initial public offerings this year.... ...The listing comes a day after the first biotech IPO of the year, in which Phase III bladder cancer drugmaker CG Oncology drew in $380 million.... ...A few more private biotechs are expected to price their listings soon, including autoimmune CAR-T maker Kyverna Therapeutics, CNS drugmaker Alto Neuroscience, obesity biotech Fractyl Health and preclinical gene editing company Metagenomi. Industry insiders anticipate more IPO filings to come in before the spring, as well.... #IPO #publicmarkets #oncology #biotech #biotechnology #therapeutics #celltherapy #cellandgenetherapy #geneediting #cartcell #cartcelltherapy #CNS #obesity #pharmaceuticals #lifesciences #healthcare #biopharma #biopharmaceuticals #financing #380m #advancedtherapies #regenerativemedicine Zhengbin (Bing) Yao

Immunology has eclipsed oncology in biotech mergers and acquisitions this year, highlighted by a notable increase in major transactions. Among notable buyouts are Merck's $10.8 billion acquisition of Prometheus Biosciences and Roche's $7.1 billion purchase of Telavant. The trend has also prompted startups like Acelyrin and Kyverna Therapeutics to make significant entries into the IPO market. Amid this shift, AltruBio stands out due to a substantial $300 million funding boost after rebranding and reconstructing its executive team. Now led by industry veterans including Judy Choud, previously with Pfizer and Bayer, and supported by Jesse Hall and Jeroen Grasman, AltruBio is advancing its groundbreaking immunotherapy, ALTB-268, targeting autoimmune diseases such as ulcerative colitis. This therapy aims to balance the immune system while preserving the body's defenses. The company eagerly anticipates the results of the Phase 2a study of ALTB-268 next year and is planning for Phase 2b in 2026. #Immunology #HealthcareInnovation #BiotechTrends

Builders w/ Paul Peter Tak, MD PhD FMedSci - President & CEO @ Candel Therapeutics 🎙️ Join us for an in-depth conversation with Paul Peter Tak, President and CEO of Candel Therapeutics, as he shares insights into the company's journey and groundbreaking innovations in viral immunotherapy. From the genesis of Candel to overcoming challenges in precision medicine, Paul Peter discusses their 'in-situ vaccination' platform and future prospects. Don't miss this episode covering leadership philosophies, strategic partnerships, and the future of biopharma. Tune in now for a glimpse into the forefront of healthcare innovation! 🚀🔬 Listen here: